Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 12, 2026
Why Is HighPeak Energy (HPK) Stock Down -10.53% Today?

Why Is HighPeak Energy (HPK) Stock Down -10.53% Today?

Key Takeaways

  • 10.53% decline: HPK fell $0.87 to $7.39 in Wednesday's session, from a prior close of $8.26.
  • Post-earnings profit-taking: The pullback followed a two-day rally that pushed shares to a 52-week high of $9.13 after second-quarter results.
  • Analyst overhang: A weekend downgrade to "sell" and mixed ratings added pressure after the run-up.
  • Thin trading amplified the move: Volume was running sharply below average.
  • Stock-specific selloff: WTI crude held near $83, so the decline diverged from a relatively firm energy tape.
  • Level to watch: The 50-day moving average near $7.27.

Opening Summary

HighPeak Energy, Inc. (HPK) is an independent oil and natural gas exploration and production company focused on the Midland Basin in West Texas. Shares of HPK fell 10.53% on Wednesday, trading at $7.39 as of mid-afternoon, down $0.87 from the previous session's close of $8.26. The move marked a sharp reversal after the stock touched a 52-week high of $9.13 the prior day, as traders locked in gains following second-quarter results. Markets attributed the decline to profit-taking after a two-session rally, a bearish analyst call, and exceptionally light trading volume.

Post-Earnings Reversal After a Two-Day Rally

The selling pressure follows a powerful run. HPK reported second-quarter results after Monday's close, topping revenue estimates, with first-half production averaging 45,500 BOE/d — above the high end of guidance — and unit lease operating expense about 13% below guided levels. Adjusted EBITDA for the first half was roughly $281 million. Investors initially bid shares up about 15% across Monday and Tuesday, culminating in Tuesday's 52-week high.

By Wednesday, the focus shifted to less favorable details: about $55 million of net cash hedge losses, a second-quarter oil cut of 64% versus the guided 67–68%, negative Waha natural gas differentials, and first-half capital spending in the mid-to-upper 60% range of the annual budget. That combination gave traders a reason to take profits.

Analyst Downgrade and Mixed Ratings

A weekend research note from Wall Street Zen cut HPK to a "sell" rating from "hold," adding an overhang after the rally. Ratings remain divided: one shop carries a Strong Buy, one a Hold, and one a Sell, with a consensus Hold and an average price target of $12.00. Weiss Ratings has maintained a "sell" rating. With the stock up sharply in a short period, the negative call reinforced the temptation to bank gains.

Market Context and Trading Activity

The decline was amplified by unusually light volume; midday figures showed trading running roughly 92% below the stock's average session pace. Thin liquidity tends to exaggerate price moves. The selloff was also stock-specific rather than sector-driven: WTI crude held near $83 a barrel, supported by Middle East supply concerns, even as OPEC and the IEA trimmed 2026 demand forecasts. Broader U.S. equities were cautious around the July consumer-price-index release.

Technically, HPK slid through the $8.00 level and approached its 50-day simple moving average near $7.27; the 200-day average sits near $6.47.

What Comes Next for HPK

Investors will watch whether HPK can hold support near its 50-day moving average after the post-earnings reset. The company expects a lower completion cadence and reduced second-half capital spending, which management says positions it for stronger free cash flow if oil prices cooperate. Key variables include the path of WTI and Permian gas differentials, progress on U.S.-Iran and Strait of Hormuz headlines, and execution on the $30 million quarterly term-loan amortization that begins in the third quarter. Next quarterly results are expected in early November. Risks include commodity-price swings, hedge-related volatility, and the company's debt load.

Trending AI Robots

Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots from a broader lineup of hundreds covering thousands of tickers. Only the strongest performers under current market conditions are highlighted. The bots vary by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see which automated strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HPK

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Aroon Indicator for HPK shows an upward move is likely

HPK's Aroon Indicator triggered a bullish signal on July 27, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator showed a similar pattern. In of the 180 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 10, 2026. You may want to consider a long position or call options on HPK as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HPK just turned positive on August 10, 2026. Looking at past instances where HPK's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

HPK moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HPK advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

HPK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for HPK crossed bearishly below the 50-day moving average on July 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HPK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HPK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.674) is normal, around the industry mean (7.499). P/E Ratio (52.231) is within average values for comparable stocks, (22.633). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.483). Dividend Yield (0.010) settles around the average of (0.086) among similar stocks. P/S Ratio (1.201) is also within normal values, averaging (5.536).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HPK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

Notable companies

The most notable companies in this group are ConocoPhillips (NYSE:COP), Canadian Natural Resources Limited (NYSE:CNQ), EOG Resources (NYSE:EOG), Occidental Petroleum Corp (NYSE:OXY), Diamondback Energy (NASDAQ:FANG), Devon Energy Corp (NYSE:DVN), EQT Corp (NYSE:EQT), Expand Energy Corporation (NASDAQ:EXE), APA Corp (NASDAQ:APA), ANTERO RESOURCES Corp (NYSE:AR).

Industry description

The oil and gas production segment includes companies that specialize in exploration, development, and production of oil and natural gas. These companies are focused on upstream operations. Companies typically identify deposits, drill wells, and extract raw materials from underground. The industry also includes related services like rig operations, feasibility studies, machinery rentals etc. Several operators in this industry work with various types of contractors such as engineering procurement and construction contractors, as well as with joint-venture partners and oil field service companies. Oil and gas often involves large fixed costs of production; so, declining crude oil prices, for example, is a potential negative for this industry. Conoco Phillips, EOG Resources, Inc. and Pioneer Natural Resources Company are some examples of companies operating in this space.

Market Cap

The average market capitalization across the Oil & Gas Production Industry is 10.05B. The market cap for tickers in the group ranges from 3.28K to 151.27B. COP holds the highest valuation in this group at 151.27B. The lowest valued company is PSTRQ at 3.28K.

High and low price notable news

The average weekly price growth across all stocks in the Oil & Gas Production Industry was 6%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 7%. GTE experienced the highest price growth at 40%, while GLND experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Oil & Gas Production Industry was -20%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 52
Price Growth Rating: 50
SMR Rating: 74
Profit Risk Rating: 72
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
HPK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry OilGasProduction

Profile
Details
Industry
N/A
Address
421 West 3rd Street
Phone
+1 817 850-9200
Employees
50
Web
https://www.highpeakenergy.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.